Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model

Esquivias,Paula; Cebrián,Carmelo; Morandeira,Antonio; Santander,Sonia; Ortego,Javier; García-González,María Asunción; Lanas,Angel; Piazuelo,Elena

doi:10.3892/or.2014.3137

Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model

Authors:
- Paula Esquivias
- Carmelo Cebrián
- Antonio Morandeira
- Sonia Santander
- Javier Ortego
- María Asunción García-González
- Angel Lanas
- Elena Piazuelo
View Affiliations

Affiliations: CIBER Enfermedades Hepáticas y Digestivas, 08036 Barcelona, Spain, Department of Pathology, University Hospital, 50009 Zaragoza, Spain, Department of Surgery, University Hospital, 50009 Zaragoza, Spain, University of Zaragoza, 50009 Zaragoza, Spain
Published online on: April 16, 2014 https://doi.org/10.3892/or.2014.3137
Pages: 2785-2791

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with Barrett's esophagus. The aim of the present study was to evaluate the effect of acetylsalicylic acid (ASA) in an experimental model of esophageal adenocarcinoma. An animal model of gastroenteroesophageal reflux was established using Wistar rats undergoing esophagojejunostomy with gastric preservation. Following surgery, rats were divided into three groups: i) control (vehicle); ii) ASA 50 mg/kg/day; and iii) ASA 5 mg/kg/day. Four months after surgery, the surviving animals were sacrificed and the rat esophagi were assessed for histological and biochemical [prostaglandin E2 (PGE2) and lipoxin A4 (LXA4 ) levels] analysis. As in the control rats, those receiving aspirin treatment showed no decrease in inflammation grade, extent of ulcerated esophageal mucosa, length of intestinal metaplasia in continuity with anastomosis, presence of intestinal metaplasia beyond anastomosis, severity of dysplasia or incidence of adenocarcinoma. In contrast, aspirin-treated rats showed decreased esophageal tissue levels of PGE2 and increased LXA4, significantly in the high-dose aspirin group (p=0.008 and p=0.01, respectively). In this rat model of gastroesophageal reflux, the administration of aspirin modified esophageal tissue levels of PGE2 and LXA4, but was not effective in preventing the development of esophageal adenocarcinoma.

View Figures

View References

1	Pera M, Manterola C, Vidal O and Grande L: Epidemiology of esophageal adenocarcinoma. J Surg Oncol. 92:151–159. 2005. View Article : Google Scholar : PubMed/NCBI
2	Blot WJ, Devesa SS, Kneller RW and Fraumeni JF Jr: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 265:1287–1289. 1991. View Article : Google Scholar : PubMed/NCBI
3	Devesa SS, Blot WJ and Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 83:2049–2053. 1998. View Article : Google Scholar : PubMed/NCBI
4	Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, Ohuchida S, Sugimoto Y, Narumiya S, Sugimura T and Wakabayashi K: Involvement of prostaglandin E receptor subtype EP₄ in colon carcinogenesis. Cancer Res. 62:28–32. 2002.PubMed/NCBI
5	Husain SS, Szabo IL and Tamawski AS: NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am J Gastroenterol. 97:542–553. 2002. View Article : Google Scholar : PubMed/NCBI
6	Piazuelo E, Jimenez P and Lanas A: COX-2 inhibition in esophagitis, Barrett’s esophagus and esophageal cancer. Curr Pharm Des. 9:2267–2280. 2003.
7	Al-Saeed A: Gastrointestinal and cardiovascular risk of nonsteroidal anti-inflammatory drugs. Oman Med. 26:385–391. 2011. View Article : Google Scholar : PubMed/NCBI
8	Patrignani P, Tacconelli S, Bruno A, Sostres C and Lanas A: Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol. 4:605–621. 2011. View Article : Google Scholar : PubMed/NCBI
9	Hennekens CH: Update on aspirin in the treatment and prevention of cardiovascular disease. Am Heart J. 137:S9–S13. 1999. View Article : Google Scholar : PubMed/NCBI
10	Dai Y and Ge J: Clinical use of aspirin in treatment and prevention of cardiovascular disease. Thrombosis. 2012:2450372012.PubMed/NCBI
11	Piazuelo E, Cebrián C, Escartín A, Jiménez P, Soteras F, Ortego J and Lanas A: Superoxide dismutase prevents development of adenocarcinoma in a rat model of Barrett’s esophagus. World J Gastroenterol. 11:7436–7443. 2005.PubMed/NCBI
12	Hindmarsh A, Belshaw N, Mehta S, Johnson IT and Rhodes M: Can the rat be used as a valid model of human esophageal adenocarcinoma? Dis Esophagus. 25:159–165. 2011. View Article : Google Scholar : PubMed/NCBI
13	Su Y, Chen X, Klein M, Fang M, Wang S, Yang CS and Goyal RK: Phenotype of columnar-lined esophagus in rats with esophagogastroduodenal anastomosis: similarity to human Barrett’s esophagus. Lab Invest. 84:753–765. 2004.PubMed/NCBI
14	Reddy BS, Rao CV, Rivenson A and Kelloff G: Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis. 14:1493–1497. 1993. View Article : Google Scholar : PubMed/NCBI
15	Barnes CJ and Lee M: Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology. 114:873–877. 1998. View Article : Google Scholar : PubMed/NCBI
16	Bousserouel S, Gosse F, Bouhadjar M, Soler L, Marescaux J and Rau F: Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis. Oncol Rep. 23:511–517. 2010.
17	Haggitt RC: Barrett’s esophagus, dysplasia, and adenocarcinoma. Hum Pathol. 25:982–993. 1994.
18	Powell WS: Reversed-phase high-pressure liquid chromatography of arachidonic acid metabolites formed by cyclooxygenase and lipoxygenases. Anal Biochem. 148:59–69. 1985. View Article : Google Scholar : PubMed/NCBI
19	Lanas AI, Arroyo MT, Esteva F, Cornudella R, Hirschowitz BI and Sáinz R: Aspirin related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use. Gut. 39:654–660. 1996. View Article : Google Scholar : PubMed/NCBI
20	Jang TJ, Min SK, Bae JD, Jung KH, Lee JI, Kim JR and Ahn WS: Expression of cyclooxygenase 2, microsomal prostaglandin E synthase 1, and EP receptors is increased in rat oesophageal squamous cell dysplasia and Barrett’s metaplasia induced by duodenal contents reflux. Gut. 53:27–33. 2004.PubMed/NCBI
21	Piazuelo E, Santander S, Cebrián C, Jiménez P, Pastor C, García-González MA, Esteva F, Esquivias P, Ortego J and Lanas A: Characterization of the prostaglandin E2 pathway in a rat model of esophageal adenocarcinoma. Curr Cancer Drug Targets. 12:132–143. 2012. View Article : Google Scholar : PubMed/NCBI
22	Wilson KT, Fu S, Ramanujam KS and Meltzer SJ: Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett’s esophagus and associated adenocarcinomas. Cancer Res. 58:2929–2934. 1998.
23	Jimenez P, Piazuelo E, Cebrian C, Ortego J, Strunk M, García-Gonzalez MA, Santander S, Alcedo J and Lanas A: Prostaglandin EP2 receptor expression is increased in Barrett’s oesophagus and oesophageal adenocarcinoma. Aliment Pharmacol Ther. 31:440–451. 2010.
24	Esquivias P, Morandeira A, Escartín A, Cebrián C, Santander S, Esteva F, García-González MA, Ortego J, Lanas A and Piazuelo E: Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats. World J Gastroenterol. 18:4866–4874. 2012. View Article : Google Scholar : PubMed/NCBI
25	Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, Krishnadath KK, Lutzke LS and Burgart LJ: Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett’s esophagus. Gastroenterology. 122:1101–1112. 2002.PubMed/NCBI
26	Oyama K, Fujimura T, Ninomiya I, Miyashita T, Kinami S, Fushida S, Ohta T and Koichi M: A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis. 26:565–570. 2005. View Article : Google Scholar : PubMed/NCBI
27	Chen X, Wang S, Wu N, Sood S, Wang P, Jin Z, Beer DG, Giordano TJ, Lin Y, Shih WC, Lubet RA and Yang CS: Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res. 10:6703–6709. 2004. View Article : Google Scholar : PubMed/NCBI
28	Patrono C and Rocca B: Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol. 28:s25–s32. 2008. View Article : Google Scholar : PubMed/NCBI
29	Claria J and Serhan CN: Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA. 92:9475–9479. 1995. View Article : Google Scholar : PubMed/NCBI
30	Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, Newson J, Bellingan G and Gilroy DW: Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol. 183:2089–2096. 2009. View Article : Google Scholar : PubMed/NCBI
31	Zhou XY, Li YS, Wu P, Wang HM, Cai ZY, Xu FY and Ye DY: Lipoxin A₄ inhibited hepatocyte growth factor-induced invasion of human hepatoma cells. Hepatol Res. 39:921–930. 2009.PubMed/NCBI
32	Chen Y, Hao H, He S, Cai L, Li Y, Hu S, Ye D, Hoidal J, Wu P and Chen X: Lipoxin A₄ and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis. Mol Cancer Ther. 9:2164–2174. 2010.PubMed/NCBI
33	Dovizio M, Tacconelli S, Sostres C, Ricciotti E and Patrignani P: Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals. 5:1346–1371. 2012. View Article : Google Scholar : PubMed/NCBI
34	Sample D, Wargovich M, Fischer SM, Inamdar N, Schwartz P, Wang X, Do KA and Sinicrope FA: A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E₂ levels as a biomarker. Cancer Epidemiol Biomarkers Prev. 11:275–279. 2002.PubMed/NCBI
35	Triadafilopoulos G, Kaur B, Sood S, Traxler B, Levine D and Weston A: The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E₂ production in patients with Barrett’s oesophagus. Aliment Pharmacol Ther. 23:997–1005. 2006. View Article : Google Scholar : PubMed/NCBI
36	Falk GW, Buttar NS, Foster NR, Ziegler KL, Demars CJ, Romero Y, Marcon NE, Schnell T, Corley DA, Sharma P, Cruz-Correa MR, Hur C, Fleischer DE, Chak A, Devault KR, Weinberg DS, Della’Zanna G, Richmond E, Smyrk TC, Mandrekar SJ and Limburg PJ; Cancer Prevention Network. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E₂in patients with Barrett’s esophagus. Gastroenterology. 143:917–926.e1. 2012. View Article : Google Scholar : PubMed/NCBI
37	Chiang N, Bermudez EA, Ridker PM, Hurwitz S and Serhan CN: Aspirin triggers antiinflammatory 15-epi-lipoxin A₄ and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci USA. 101:15178–15183. 2004. View Article : Google Scholar : PubMed/NCBI
38	Souza MH, de Lima OM Jr, Zamuner SR, Fiorucci S and Wallace JL: Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. Am J Physiol Gastrointest Liver Physiol. 285:G54–G61. 2003. View Article : Google Scholar : PubMed/NCBI
39	Fiorucci S, de Lima OM Jr, Mencarelli A, Palazzetti B, Distrutti E, McKnight W, Dicay M, Ma L, Romano M, Morelli A and Wallace JL: Cyclooxygenase-2-derived lipoxin A₄ increases gastric resistance to aspirin-induced damage. Gastroenterology. 123:1598–1606. 2002.PubMed/NCBI
40	Pawlik M, Pajdo R, Kwiecien S, Ptak-Belowska A, Sliwowski Z, Mazurkiewicz-Janik M, Konturek SJ, Pawlik WW and Brzozowski T: Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines. J Physiol Pharmacol. 62:75–86. 2011.
41	Rizvi S, Demars CJ, Comba A, Gainullin VG, Rizvi Z, Almada LL, Wang K, Lomberk G, Fernández-Zapico ME and Buttar NS: Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis. Cancer Res. 70:6787–6796. 2010. View Article : Google Scholar : PubMed/NCBI
42	Sugimoto M, Nishino M, Kodaira C, Yamade M, Ikuma M, Tanaka T, Sugimura H, Hishida A and Furuta T: Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. J Clin Pharmacol. 50:320–330. 2010. View Article : Google Scholar : PubMed/NCBI
43	Kawai T, Watanabe M and Yamashina A: Impact of upper gastrointestinal lesions in patients on low-dose aspirin therapy: preliminary study. J Gastroenterol Hepatol. 25(Suppl 1): S23–S30. 2010. View Article : Google Scholar : PubMed/NCBI
44	Lanas A, Jiménez P, Ferrández A, Escartín A, Arenas J, Esteva F and Ortego J: Selective COX-2 inhibition is associated with decreased mucosal damage induced by acid and pepsin in rabbit esophagitis. Inflammation. 27:21–29. 2003. View Article : Google Scholar : PubMed/NCBI
45	Zhang DH, Zhou LY, Dong XY, Cui RL, Xue Y and Lin SR: Factors influencing intercellular spaces in the rat esophageal epithelium. World J Gastroenterol. 16:1063–1069. 2010. View Article : Google Scholar : PubMed/NCBI
46	Pohle T, Brzozowski T, Becker JC, Van der Voort IR, Markmann A, Konturek SJ, Moniczewski A, Domschke W and Konturek JW: Role of reactive oxygen metabolites in aspirin-induced gastric damage in humans: gastroprotection by vitamin C. Aliment Pharmacol Ther. 15:677–687. 2001. View Article : Google Scholar : PubMed/NCBI
47	Raza H, John A and Benedict S: Acetylsalicylic acid-induced oxidative stress, cell cycle arrest, apoptosis and mitochondrial dysfunction in human hepatoma HepG2 cells. Eur J Pharmacol. 668:15–24. 2011. View Article : Google Scholar